Breaking the Bottleneck: Scientists Successfully Cultivate “Self - Sustaining Blood - Supplying” Liver Tissue
Release time:
2025-07-11
An international research team composed of four top - tier institutions, namely Cincinnati Children's Hospital, Icahn School of Medicine at Mount Sinai, Tokyo Institute of Science, and Takeda Pharmaceutical Company, has achieved a revolutionary breakthrough in the field of organoid technology. The team published their latest research findings in Nature Biomedical Engineering, successfully cultivating liver organoids with a functional vascular network, which paves a new way for the treatment of hemophilia and liver regenerative medicine.
The key to this decade - long technological breakthrough lies in the innovative development of the IMALI (Inverted Multilayer Air - Liquid Interface) culture system. By mimicking the natural development environment of the human body, this system has enabled, for the first time, the differentiation of human pluripotent stem cells into hepatic sinusoidal endothelial precursor cells (iLSEPs), which then self - assemble to form hepatic liver organoids (HLBOs) containing central vein - like structures and sinusoidal vascular networks. Research data indicate that these organoids can secrete multiple key coagulation factors, including factor VIII (FVIII). Moreover, they can significantly improve the coagulation function in a hemophilia mouse model, notably reducing the bleeding time of the experimental animals.
Dr. Takebe stated, "Our research has taken a significant step in understanding and replicating the complex cell - to - cell interactions that occur during liver development. The ability to generate functional sinusoidal blood vessels opens up new possibilities for a wide range of human biology and disease modeling, as well as for treating coagulation disorders."
Experts suggest that the clinical value of this technology is manifested in three aspects: it offers potential new treatment options for patients with hemophilia A; it facilitates the development of transplantable organoid tissues for patients with liver failure; and it promotes the advancement of personalized medicine.This groundbreaking achievement not only resolves the long - standing issue of organoid vascularization but also provides a reproducible culture model for the field of regenerative medicine. It is expected to enter the clinical trial phase within the next five years.
Latest developments
Recently, Frigid Zone Medicine, an authoritative international journal in the field of cryomedicine, published an important review titled "Advances in the Detection Methods for Assessing the Viability of Cryopreserved Samples". Written by the team of Yinfeng Cryomedical Research Center, the article systematically reviews and analyzes various detection techniques currently used to evaluate the viability of cryopreserved cells, tissues, and organs. It also proposes key directions from the perspectives of methodological integration and future instrument development, offering crucial theoretical support and practical guidance for the long - term cryopreservation of complex tissues and organs.
Recently, the "Novel Technology for Ultra-Low Temperature Cryopreservation, Activation, and Transplantation of Human Ovarian Tissue," developed through a collaborative effort between Shandong Yinfeng Life Science Research Institute and Beijing University of Chinese Medicine Shenzhen Hospital, has been awarded the 2025 Shandong Refrigeration and Air Conditioning Science and Technology Award. This groundbreaking technology pioneers a new pathway for female fertility preservation, marking a significant leap in China’s interdisciplinary advancements in reproductive medicine and cryobiology.
On May 19, a delegation from the Chinese Training Workshop for Government Officials of Developing Countries visited the exhibition hall of Yinfeng Biological Group's Cryomedicine Research Center. Government officials from multiple countries gained in-depth insights into Yinfeng’s innovative achievements in cryobiomedicine, cell storage, genetic technology, and other fields. They engaged in discussions with the delegation on technology transfer and international cooperation, contributing to the building of a global community with a shared future for humanity.
On the morning of May 17, 2025, an immersive exploration into life sciences and cryomedicine concluded successfully at Jinan Yinfeng Biological Science Park. Hosted by the Shandong Yinfeng Life Science Research Institute, this event offered members a firsthand look into the research base through activities such as ultra-low temperature cryotherapy experiences, brainwave signal acquisition system trials, and expert panel discussions. Participants witnessed the infinite possibilities that cryogenic technology and life sciences hold for humanity.
The international academic platform ScholarGPS recently announced its global lists of Highly Ranked Scholars - Lifetime and Highly Ranked Scholars - Prior 5 Years, recognizing the top 0.05% of scholars across various disciplines. Among the selected Chinese scholars are national-level talents, leading figures in specialized fields, and seasoned academics dedicated to long-term research.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
